U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07363434) titled 'A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib' on Jan. 16.
Brief Summary: The aim of this study was to assess the effectiveness, safety, and tolerability of ribociclib in Indian women with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (aBC).
This study used secondary data sources, i.e., paper-based records; electronic medical records (EMRs); and other sources, such as radiology reports, pathology reports, and examination/clinician notes related to aBC, from clinics/hospitals across 18 sites in India. Aggregated data of...